Baclofen and gamma-hydroxybutyrate withdrawal

Jennifer L. LeTourneau, Daniel Hagg, Stephen Smith

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Introduction: Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy. Methods: A case report from the medical intensive care unit (ICU) of the university tertiary care hospital. Results: A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor. Conclusions: Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.

Original languageEnglish (US)
Pages (from-to)430-433
Number of pages4
JournalNeurocritical Care
Volume8
Issue number3
DOIs
StatePublished - Jun 2008

Fingerprint

Sodium Oxybate
Baclofen
Delirium
Tremor
Benzodiazepines
Intensive Care Units
Seizures
Substance Withdrawal Syndrome
Tertiary Healthcare
Therapeutics
Tertiary Care Centers

Keywords

  • Baclofen
  • Gamma-hydroxybutyrate dependence
  • Intention tremor

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Baclofen and gamma-hydroxybutyrate withdrawal. / LeTourneau, Jennifer L.; Hagg, Daniel; Smith, Stephen.

In: Neurocritical Care, Vol. 8, No. 3, 06.2008, p. 430-433.

Research output: Contribution to journalArticle

LeTourneau, Jennifer L. ; Hagg, Daniel ; Smith, Stephen. / Baclofen and gamma-hydroxybutyrate withdrawal. In: Neurocritical Care. 2008 ; Vol. 8, No. 3. pp. 430-433.
@article{87071ff25b7b401cb89967717e897018,
title = "Baclofen and gamma-hydroxybutyrate withdrawal",
abstract = "Introduction: Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy. Methods: A case report from the medical intensive care unit (ICU) of the university tertiary care hospital. Results: A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor. Conclusions: Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.",
keywords = "Baclofen, Gamma-hydroxybutyrate dependence, Intention tremor",
author = "LeTourneau, {Jennifer L.} and Daniel Hagg and Stephen Smith",
year = "2008",
month = "6",
doi = "10.1007/s12028-008-9062-2",
language = "English (US)",
volume = "8",
pages = "430--433",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Baclofen and gamma-hydroxybutyrate withdrawal

AU - LeTourneau, Jennifer L.

AU - Hagg, Daniel

AU - Smith, Stephen

PY - 2008/6

Y1 - 2008/6

N2 - Introduction: Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy. Methods: A case report from the medical intensive care unit (ICU) of the university tertiary care hospital. Results: A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor. Conclusions: Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.

AB - Introduction: Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy. Methods: A case report from the medical intensive care unit (ICU) of the university tertiary care hospital. Results: A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor. Conclusions: Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.

KW - Baclofen

KW - Gamma-hydroxybutyrate dependence

KW - Intention tremor

UR - http://www.scopus.com/inward/record.url?scp=51449123237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51449123237&partnerID=8YFLogxK

U2 - 10.1007/s12028-008-9062-2

DO - 10.1007/s12028-008-9062-2

M3 - Article

C2 - 18266111

AN - SCOPUS:51449123237

VL - 8

SP - 430

EP - 433

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 3

ER -